



Alert: Extortion Scam Targeting DEA Registrants (July 28, 2020 Release)

[Read more here](#)

Join Us!

**Virtual Biweekly MAT Lunch Hours
Wednesdays 12-1pm**

Open forum featuring guest speakers to discuss MAT and an opportunity to network with other providers.
All are welcome!

Next Forum: August 5th

Featuring a discussion on **The Impact of Racial Inequities on the SUD Treatment Landscape** with Sheila Vakharia, PhD, Deputy Director of Research and Academic Engagement at Drug Policy Alliance

[Click here for the flyer!](#)



Concerned with highly potent synthetic opioids (HPSOs) like fentanyl affecting buprenorphine induction?

There is a lack of data available for the use of MAT in HPSOs. [Recent literature](#) suggests that fentanyl has a much longer renal clearance than other short-acting opioids, leading to a higher risk of precipitated withdrawal during induction. If you need guidance in inducting a fentanyl-using patient on buprenorphine, please contact the MAT Provider Hotline at 866-221-2611.



"Which Medication for Opioid Use Disorder is Right for Me?" Patient Guide

An illustrative patient guide to help patients differentiate the types of MAT.

[Download](#)



All OBAT Navigators must be approved by Medicaid by September 2020

Click below to fill out the Navigator Provider Addendum.

[Navigator Provider Addendum](#)

MAT Provider Hotline: 866-221-2611



**NORTHERN NJ
MAT CENTER OF EXCELLENCE**
Coe@njms.rutgers.edu

RUTGERS
New Jersey Medical School



**SOUTHERN NJ
MAT CENTER OF EXCELLENCE**
Southernnjcoe@rowan.edu

Cooper
University Health Care
Rowan Medicine